{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:00:31Z","timestamp":1790643631233,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical trials during public health emergencies of novel medical products such as therapeutics and vaccines in resource-limited settings are daunting due to the limited capacity for regulatory assessment. Regulating clinical trials during the Ebola outbreak in Sierra Leone required expedited evaluation to identify medical products that could be promptly introduced to combat the epidemic in the absence of approved treatment or prevention. This article explored the decisions taken by the Pharmacy Board of Sierra Leone through its Expert Committee on Medicine Safety and Clinical Trials regarding clinical trials oversight during the Ebola epidemic and the lessons learned. This independent expert committee assessed and provided scientific opinions to the Pharmacy Board of Sierra Leone to inform approval of all clinical trials within 10\u201315 working days. We also requested for assisted review from the African Vaccine Regulatory Forum and support from the US Food and Drug Administration through a unilateral recognition and reliance memorandum of understanding. In addition, the Agency-ensured structures and systems were in place for reporting and reviewing adverse events and serious adverse events, management of biological samples, submission and review of progress reports, and good clinical practice inspections. Unfortunately, the Ebola epidemic revealed many weaknesses in the country\u2019s clinical trials regulatory structure and processes. Government and partners should further offer more resources to build the clinical trial structures and systems so that the Agency will be better poised to handle future public health emergencies.<\/jats:p>","DOI":"10.1186\/s13063-022-06416-4","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T06:02:29Z","timestamp":1654495349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Regulating clinical trials in a resource-limited setting during the Ebola public health emergency in Sierra Leone"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6057-7344","authenticated-orcid":false,"given":"Onome T.","family":"Abiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulai J.","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durodami R.","family":"Lisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Komeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiltshire C. N.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheku S.","family":"Mansaray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Sam","family":"Kanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B. W.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawzi","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtada M.","family":"Sesay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Conteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alphan","family":"Tejan-Kella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Sesay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Ghazzawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorie","family":"Conteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gibrilla Fadlu","family":"Deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"6416_CR1","unstructured":"World Health Organisation (WHO). Sierra Leone: a traditional healer and a funeral, 2015, https:\/\/www.who.int\/news\/item\/01-09-2015-sierra-leone-a-traditional-healer-and-a-funeral (Accessed 1 Sep 2021)."},{"key":"6416_CR2","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1093\/cid\/ciz678","volume":"70","author":"A Forna","year":"2020","unstructured":"Forna A, Nouvellet P, Dorigatti I, Donnelly CA. Case fatality ratio estimates for the 2013-2016 west African Ebola epidemic: application of boosted regression trees for imputation. Clin Infect Dis. 2020;70:2476\u201383. https:\/\/doi.org\/10.1093\/cid\/ciz678.","journal-title":"Clin Infect Dis"},{"key":"6416_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/cid\/civ319","volume":"61","author":"E Qin","year":"2015","unstructured":"Qin E, Bi J, Zhao M, et al. Clinical features of patients with Ebola virus disease in Sierra Leone. Clin Infect Dis. 2015;61:491\u20135. https:\/\/doi.org\/10.1093\/cid\/civ319.","journal-title":"Clin Infect Dis"},{"key":"6416_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1056\/NEJMc1413685","volume":"372","author":"R Ansumana","year":"2015","unstructured":"Ansumana R, Jacobsen KH, Sahr F, et al. Ebola in Freetown area, Sierra Leone--a case study of 581 patients. N Engl J Med. 2015;372:587\u20138. https:\/\/doi.org\/10.1056\/NEJMc1413685.","journal-title":"N Engl J Med"},{"key":"6416_CR5","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa1411680","volume":"371","author":"JS Schieffelin","year":"2014","unstructured":"Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092\u2013100. https:\/\/doi.org\/10.1056\/NEJMoa1411680.","journal-title":"N Engl J Med"},{"key":"6416_CR6","unstructured":"United States Centre for Disease Prevention and Control (USCDC). 2014 Ebola outbreak in West Africa report cases graphs, 2016, http:\/\/medbox.iiab.me\/modules\/en-cdc\/www.cdc.gov\/vhf\/ebola\/outbreaks\/2014-west-africa\/cumulative-cases-graphs.html (Accessed 25 July 2021)."},{"key":"6416_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1740774518780678","volume":"15","author":"T Mooney","year":"2018","unstructured":"Mooney T, Smout E, Leigh B, et al. EBOVAC-Salone: lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country. Clin Trials. 2018;15:436\u201343.","journal-title":"Clin Trials"},{"key":"6416_CR8","unstructured":"World Health Organization. WHO Global Benchmarking Tool (GBT) for evaluation of national regulatory systems of medical products clinical trial oversight: revision VI. (2021). Available online at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/341243\/9789240020245-eng.pdf?sequence=1 (Accessed 25 Oct 2021)."},{"key":"6416_CR9","first-page":"3","volume-title":"Drug repurposing hypothesis molecular aspects and therapeutic applications","author":"M Rudrapal","year":"2020","unstructured":"Rudrapal M, Khairnar JS, Jadhav GA. Drug repurposing: an emerging approach in drug discovery. In: Badria FA, editor. Drug repurposing hypothesis molecular aspects and therapeutic applications. London: IntechOpen; 2020. p. 3\u201320."},{"key":"6416_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41587-019-0081-7","volume":"37","author":"CR Chapman","year":"2019","unstructured":"Chapman CR, Moch KI, McFadyen A, et al. What compassionate use means for gene therapies. Nat Biotechnol. 2019;37:352\u20135. https:\/\/doi.org\/10.1038\/s41587-019-0081-7.","journal-title":"Nat Biotechnol"},{"key":"6416_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13104-017-2687-5","volume":"10","author":"JE Miller","year":"2017","unstructured":"Miller JE, Ross JS, Moch KI, Caplan AL. Characterising expanded access and compassionate use programs for experimental drugs. BMC Res Notes. 2017;10:350. https:\/\/doi.org\/10.1186\/s13104-017-2687-5.","journal-title":"BMC Res Notes"},{"key":"6416_CR12","unstructured":"International Conference on Harmonisation (ICH). International Conference on Harmonisation Guidelines. 2021, https:\/\/ich.org\/ (28 Aug 2021)."},{"key":"6416_CR13","unstructured":"World Health Organisation (WHO). WHO guidelines on nonclinical evaluation of vaccines, Annex 1, TRS 927, https:\/\/www.who.int\/publications\/m\/item\/nonclinical-evaluation-of-vaccines-annex-1-trs-no-927 (2005, accessed 1st September 2021)."},{"key":"6416_CR14","unstructured":"World Health Organisation (WHO). Guidelines on clinical evaluation of vaccines: regulatory expectations, (2017). Technical Report Series 1004, Annex 9, 2017. https:\/\/www.who.int\/publications\/m\/item\/WHO-TRS-1004-web-annex-9 (Accessed 10 Sep 2021)"},{"key":"6416_CR15","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.293.23.jed50037","volume":"293","author":"CD DeAngelis","year":"2005","unstructured":"DeAngelis CD, Drazen JM, Frizelle FA, et al. Is this clinical trial fully registered?: a statement from the International Committee of Medical Journal Editors. Jama. 2005;293:2927\u20139.","journal-title":"Jama"},{"key":"6416_CR16","unstructured":"International Conference on Harmonisation (ICH). Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2), 2016, https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf (Accessed 5 Sep 2021)."},{"key":"6416_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40545-019-0173-2","volume":"12","author":"OT Abiri","year":"2019","unstructured":"Abiri OT, Johnson WCN. Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone. J Pharmaceut Policy Pract. 2019;12:13. https:\/\/doi.org\/10.1186\/s40545-019-0173-2.","journal-title":"J Pharmaceut Policy Pract"},{"key":"6416_CR18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/pds.3982","volume":"25","author":"S Cr\u00e9pin","year":"2016","unstructured":"Cr\u00e9pin S, Villeneuve C, Merle L. Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal. Pharmacoepidemiol Drug Saf. 2016;25:719\u201324.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6416_CR19","doi-asserted-by":"publisher","first-page":"e41174","DOI":"10.1371\/journal.pone.0041174","volume":"7","author":"JB Schroll","year":"2012","unstructured":"Schroll JB, Maund E, G\u00f8tzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS One. 2012;7:e41174.","journal-title":"PLoS One"},{"key":"6416_CR20","doi-asserted-by":"crossref","unstructured":"Akanmori BD, Mukanga D, Bellah A, Traore T, Ward M, Mihigo R. The role of the African vaccine regulatory forum (AVAREF) in the accelerated clinical evaluation of Ebola vaccine candidates during the large West Africa epidemic. J Immunol Sci. 2018;S(011):75-79.","DOI":"10.29245\/2578-3009\/2018\/si.1111"},{"issue":"1","key":"6416_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12910-021-00645-z","volume":"22","author":"S Singh","year":"2021","unstructured":"Singh S, Moodley K. Stakeholder perspectives on the ethico-legal dimensions of biobanking in South Africa. BMC Med Ethics. 2021;22(1):1\u20133.","journal-title":"BMC Med Ethics"},{"issue":"1","key":"6416_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/23779497.2016.1228431","volume":"1","author":"A Abayomi","year":"2016","unstructured":"Abayomi A, Katz R, Spence S, Conton B, Gevao SM. Managing dangerous pathogens: challenges in the wake of the recent west African Ebola outbreak. Glob Secur Health Sci Policy. 2016;1(1):51\u20137.","journal-title":"Glob Secur Health Sci Policy"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06416-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06416-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06416-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T06:06:25Z","timestamp":1654495585000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06416-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6416"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06416-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"29 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"466"}}